• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by AbbVie Inc.

    3/24/25 4:28:59 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    DEFA14A 1 tmb-20250324xdefa14a.htm DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    SCHEDULE 14A

    ​

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.     )

    ​

    Filed by the Registrant  x

     

    Filed by a Party other than the Registrant  o

     

    Check the appropriate box:

    o

    Preliminary Proxy Statement

    o

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    o

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    o

    Soliciting Material under §240.14a-12

     

    AbbVie Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    x

    No fee required.

    o

    Fee paid previously with preliminary materials.

    o

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

    ​


    GRAPHIC

    Your Vote Counts! ABBVIE INC. 2025 Annual Meeting For holders as of March 10, 2025 Vote by May 8, 2025 11:59 PM ET. For shares held in a Plan, vote by May 6, 2025 11:59 PM ET. You invested in ABBVIE INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 9, 2025. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # ABBVIE INC. 1 NORTH WAUKEGAN ROAD NORTH CHICAGO, IL 60064 V68972-P24556 Vote Virtually at the Meeting* May 9, 2025 9:00 AM CT Virtually at: www.virtualshareholdermeeting.com/ABBV2025 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote This is only an overview of the more complete proxy materials, which contain important information. View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 25, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V68973-P24556 1. Election of Class I Directors Nominees: 1a. William H.L. Burnside For 1b. Thomas C. Freyman For 1c. Brett J. Hart For 1d. Edward J. Rapp For 2. Ratification of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2025 For 3. Say on Pay – An advisory vote on the approval of executive compensation For 4. Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting For 5. Stockholder Proposal – to Implement Simple Majority Vote Against

    Get the next $ABBV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    5/14/2025$205.00Buy → Neutral
    Citigroup
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    11/4/2024Hold → Buy
    Argus
    10/17/2024$203.00Mkt Perform
    Bernstein
    More analyst ratings

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AbbVie downgraded by Citigroup with a new price target

      Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00

      5/14/25 8:54:15 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00

      4/22/25 7:59:33 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on AbbVie with a new price target

      BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00

      12/10/24 8:12:28 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

      Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseasesProposed acquisition strengthens AbbVie's commitment to transforming the future of patient care with Capstan's innovative tLNP platform technologyNORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a

      6/30/25 8:31:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

      SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injectable treatment option aiming to reduce neck lines.The application for indication expansion is supported by a clinical study that met all primary and secondary endpoints assessing SKINVIVE by JUVÉDERM® in adults with neck lines seeking improvement in neck appearance.1IRVINE, Calif., June 30, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemen

      6/30/25 8:25:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host Second-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

      6/30/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care